Biocryst Pharmaceuticals INC Form 4 insider transactions

Director Vincent Milano increased his holdings in BioCryst Pharmaceuticals by purchasing 15,000 shares at an average price of $6.25 on May 20, 2024.

Anthony Doyle, CFO of BioCryst Pharmaceuticals, recently purchased 36,300 shares of the company's common stock at a price of $5.57 per share.

Helen M. Thackray, Chief R&D Officer of BioCryst Pharmaceuticals, recently acquired 30,000 shares of common stock at an average price of $5.86.

Director Steven K. Galson of BioCryst Pharmaceuticals Inc. recently purchased 21,940 shares of common stock at an average price of $5.49.

Alane P. Barnes, Chief Legal Officer of BioCryst Pharmaceuticals, recently acquired 5,000 shares of common stock at an average price of $5.53 per share, increasing her total holdings to 300,762 shares.

BioCryst Pharmaceuticals' CEO, Jon P. Stonehouse, recently acquired 30,000 shares of common stock, increasing his direct holdings.

Chief Commercial Officer of BioCryst Pharmaceuticals, Charles K. Gayer, purchased 30,000 shares of common stock at $5.47 per share on May 13, 2024.

Helen M. Thackray, Chief R&D Officer of BioCryst Pharmaceuticals, reports a transaction involving the withholding of shares to cover tax obligations related to vested Restricted Stock Units.

Director Vincent Milano acquired 999 shares of BioCryst Pharmaceuticals common stock in lieu of a portion of his quarterly cash retainer.

Director Theresa Heggie acquired 999 shares of BioCryst Pharmaceuticals Inc. common stock on February 29, 2024, in lieu of a portion of her quarterly board member retainer.